For this reason, recombinant ACE2 has been proposed as a treatment for PAH, with the aim to reduce pulmonary vascular remodeling and microvasculature thrombosis, leading to V/Q disturbances [79]. The gene discussed is ACE2; the disease is pulmonary arterial hypertension.